FY2026 EPS Estimates for Precigen Decreased by Analyst

Key Points

• Cantor Fitzgerald has revised its FY2026 earnings estimate for Precigen to $0.07 per share, down from $0.11, while maintaining an "Overweight" rating on the stock.
• Precigen recently reported $0.86 million in revenue for the quarter, exceeding analyst estimates, and had a negative net margin of 2,868.66%.
• Several research firms have upgraded their ratings and price targets for Precigen, with JMP Securities raising its target from $6.00 to $8.00.

Precigen, Inc. (NASDAQ:PGEN - Free Report) - Equities researchers at Cantor Fitzgerald cut their FY2026 earnings per share (EPS) estimates for Precigen in a report issued on Tuesday, August 19th. Cantor Fitzgerald analyst J. Kim now forecasts that the biotechnology company will post earnings of $0.07 per share for the year, down from their prior forecast of $0.11. Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Precigen's current full-year earnings is ($0.32) per share.

A number of other equities analysts also recently commented on the company. Citigroup reiterated an "outperform" rating on shares of Precigen in a research report on Tuesday, August 19th. HC Wainwright reiterated a "buy" rating and set a $8.50 price objective on shares of Precigen in a research report on Tuesday, August 19th. Wall Street Zen upgraded Precigen from a "sell" rating to a "hold" rating in a research report on Saturday, July 12th. JMP Securities lifted their price objective on Precigen from $6.00 to $8.00 and gave the stock a "market outperform" rating in a research report on Tuesday, August 19th. Finally, JPMorgan Chase & Co. upgraded Precigen from an "underweight" rating to a "neutral" rating in a research report on Friday, August 15th. Four research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $8.25.

Precigen Stock Performance

Shares of NASDAQ:PGEN traded down $0.0210 during trading on Wednesday, reaching $4.1590. The stock had a trading volume of 5,891,514 shares, compared to its average volume of 3,634,508. Precigen has a 1-year low of $0.65 and a 1-year high of $4.30. The stock has a market cap of $1.24 billion, a PE ratio of -9.94 and a beta of 1.87. The business has a fifty day moving average price of $1.87 and a 200-day moving average price of $1.67.

Precigen (NASDAQ:PGEN - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.14) by $0.03. The firm had revenue of $0.86 million for the quarter, compared to analyst estimates of $0.67 million. Precigen had a negative return on equity of 842.83% and a negative net margin of 2,868.66%.

Institutional Investors Weigh In On Precigen

Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets purchased a new stake in shares of Precigen in the 4th quarter valued at $27,000. Envestnet Asset Management Inc. raised its holdings in shares of Precigen by 29.0% in the 4th quarter. Envestnet Asset Management Inc. now owns 26,343 shares of the biotechnology company's stock valued at $30,000 after buying an additional 5,915 shares during the period. Apella Capital LLC purchased a new stake in shares of Precigen in the 1st quarter valued at $40,000. Boothbay Fund Management LLC purchased a new stake in shares of Precigen in the 4th quarter valued at $35,000. Finally, Voya Investment Management LLC raised its holdings in shares of Precigen by 142.9% in the 1st quarter. Voya Investment Management LLC now owns 36,771 shares of the biotechnology company's stock valued at $55,000 after buying an additional 21,633 shares during the period. Hedge funds and other institutional investors own 33.51% of the company's stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.